See cancer.
On Target Laboratories’s fluorescent imaging technology illuminates cancer during surgery, potentially enabling surgeons to see and remove more diseased tissue.
Surgeons step into the OR with a variety of pre-operative inputs that help locate tumors and suspicious lesions — but finding small lesions can still be challenging.
By targeting and illuminating cancerous tissue during a procedure, On Target’s technology has the potential to give skilled surgeons the added benefit of intraoperative sight. This added visibility may increase the likelihood of a more complete surgical resection. Complete resections are associated with reduced re-operations or adjuvant treatments1, and for patients translate into increased survival.
Increase in Survival After Complete Resection
In Lung Cancer
1.75X
Greater 5-Year
Survival Rates2
In Ovarian Cancer
1.75-3X
Greater Median
5-Year Survival3
FOOTNOTES
1 Riquet, Mark, et al. Microscopic Residual Disease After Resection for Lung Cancer: A Multifaceted but Poor Factor of Prognosis. Ann Thorac Surg. 2010;89: 870-6. doi:10.1016/j.athoracsur.2009.12.037
2 Osarogiagbon RU, Lin CC, Smeltzer MP, Jemal A. Prevalence, Prognostic Implications and Survival Modulators of Incompletely Resected Non-small-cell Lung Cancer in the US National Cancer Data Base. Journal of Thoracic Oncology. 2016;11: e5-16. doi: 10.1016/j.jtho.2015.08.002.
3 Roche KL, Gardner GJ. State of the Science: Evolving Role of Surgery for the Treatment of Ovarian Cancer. Gynecologic Oncology. 2019;155(1): pp 3-7.
On Target’s technology gives surgeons intraoperative visibility of cancerous tissue, potentially increasing the chance for a complete surgical resection.
Designed By
Designer
Developed By
Alchemy + Aim